Specific immunotherapy using Hymenoptera venom: systematic review

Watanabe, Alexandra Sayuri; Fonseca, Luiz Augusto Marcondes; Galvão, Clóvis Eduardo Santos; Kalil, Jorge; Castro, Fábio Fernandes Morato

doi:10.1590/s1516-31802010000100007

Cited by 25 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fatal sting anaphylaxis is estimated to occur in between two and nine individuals in the UK each year, 15 and because of the rarity of this outcome it is therefore not possible to conclude from the data presented in either the current review or previous systematic reviews 33,71,72 whether PhVIT prevents fatal sting anaphylaxis.…”

Section: Discussion Of Clinical Results and Key Issuesmentioning

confidence: 93%

“…Two systematic reviews 33,72 and a meta-analysis 71 have concluded that VIT is effective in preventing future systemic reactions to venom in venom-allergic people; however, these studies included all types of VIT and it may not be possible to generalise the findings of these reviews to PhVIT because of differences in venom extracts and concentrations and differences in administration methods. The AG notes that venom products for use in VIT are manufactured by several different companies, and some companies produce more than one venom product.…”

Section: Discussion Of Clinical Results and Key Issuesmentioning

confidence: 99%

“…Three studies 55- Comparative studies of venom immunotherapy other than Pharmalgen Although the remit of this review was to assess the clinical effectiveness and cost-effectiveness of PhVIT for the treatment of bee and wasp venom allergy, as discussed in Chapter 1, Venom immunotherapy, there are other VIT products that are available to treat bee and wasp venom allergy. The searches for this review identified one meta-analysis 71 and two systematic reviews 33,72 reporting on comparative studies of non-PhVIT products in the population of interest, and an overview of the publications is given in Table 14.…”

Section: Observational Studies Of Pharmalgenmentioning

confidence: 99%

“…The AG assessed the systematic reviews 33,72 for quality using the Database of Abstracts of Reviews of Effects (DARE) quality assessment tool. 88 Both were shown to be of high quality ( Table 15).…”

Section: Observational Studies Of Pharmalgenmentioning

confidence: 99%

“…Both of the systematic reviews 33,72 and the meta-analysis 71 conclude that VIT is effective in preventing future systemic reactions to venom in venom-allergic people.…”

Section: Observational Studies Of Pharmalgenmentioning

confidence: 99%

See 4 more Smart Citations

A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.

Hockenhull

Elremeli²,

Cherry³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are ...

show abstract

Section: Discussion Of Clinical Results and Key Issuesmentioning

confidence: 93%

Section: Discussion Of Clinical Results and Key Issuesmentioning

confidence: 99%

Section: Observational Studies Of Pharmalgenmentioning

confidence: 99%

Section: Observational Studies Of Pharmalgenmentioning

confidence: 99%

“…Both of the systematic reviews 33,72 and the meta-analysis 71 conclude that VIT is effective in preventing future systemic reactions to venom in venom-allergic people.…”

Section: Observational Studies Of Pharmalgenmentioning

confidence: 99%

See 3 more Smart Citations

A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.

Hockenhull

Elremeli²,

Cherry³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

show abstract

Venom immunotherapy for preventing allergic reactions to insect stings

Boyle

Elremeli

Hockenhull

et al. 2012

Cochrane Database of Systematic Reviews

125

122

View full text Add to dashboard Cite

Venom immunotherapy compared with no venom immunotherapy for insect sting allergy Patient or population: adults and children with a previous allergic reaction to an insect sting Setting: allergy ref erral units in USA (3 trials), Netherlands (2 trials), Italy, and Australia Intervention: venom im m unotherapy Comparison: no venom im m unotherapy Outcomes Illustrative comparative risks* (95% CI) Relative effect (95% CI) No of Participants (studies) Quality of the evidence (GRADE) Comments Assumed risk Corresponding risk No venom immunotherapy Venom immunotherapy Any systemic reaction to an insect sting Follow-up: between 6 weeks and 4 years Low-risk population RR 0.10 (0.03 to 0.28) 206 (7) ⊕⊕⊕⊕ high a-83 per 1000 8 per 1000 (2 to 23) M edium-risk population 398 per 1000 40 per 1000 (12 to 111) High-risk population 724 per 1000 72 per 1000 (22 to 203) Large local reaction Follow-up: between 12 weeks and 4 years Low-risk population RR 0.41 (0.24 to 0.69) 112 (5) ⊕⊕⊕ moderate b-3 Venom immunotherapy for preventing allergic reactions to insect stings (Review)

show abstract